Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ekso Bionics Holdings (EKSO) FCF Margin (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed FCF Margin for 13 consecutive years, with 141.94% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin fell 11338.0% to 141.94% in Q4 2025 year-over-year; TTM through Dec 2025 was 93.67%, a 3854.0% decrease, with the full-year FY2025 number at 93.67%, down 3854.0% from a year prior.
  • FCF Margin was 141.94% for Q4 2025 at Ekso Bionics Holdings, down from 49.04% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 28.57% in Q4 2024 to a low of 169.37% in Q2 2025.
  • A 5-year average of 92.03% and a median of 82.04% in 2022 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: skyrocketed 7054bps in 2023, then crashed -11543bps in 2025.
  • Ekso Bionics Holdings' FCF Margin stood at 81.17% in 2021, then decreased by -28bps to 104.11% in 2022, then surged by 68bps to 33.57% in 2023, then grew by 15bps to 28.57% in 2024, then plummeted by -397bps to 141.94% in 2025.
  • Per Business Quant, the three most recent readings for EKSO's FCF Margin are 141.94% (Q4 2025), 49.04% (Q3 2025), and 169.37% (Q2 2025).